ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1412

Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study

Stanley Cohen1, Janet Pope 2, Boulos Haraoui 3, Eduardo Mysler 4, Annette Diehl 5, Tatjana Lukic 6, Shixue Liu 7, Lori Stockert 5, Sujatha Menon 8 and Edward Keystone 9, 1Metroplex Clinical Research Center, Dallas, TX, 2Western University, London, ON, Canada, 3Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 4Organización Médica de Investigación, Buenos Aires, Argentina, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Shanghai, China (People's Republic), 8Pfizer Inc, Groton, CT, 9Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Rheumatoid arthritis (RA), tofacitinib and Janus kinase (JAK)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The tofacitinib modified-release (MR) 11 mg once daily (QD) formulation was first approved in the US in 2016 for the treatment of patients (pts) with moderate to severe RA and an inadequate response or intolerance to MTX. ORAL Shift is the first global study of tofacitinib MR 11 mg QD + MTX. Efficacy and pt-reported outcomes (PROs), and safety, from the open-label (OL) phase of ORAL Shift are reported here.

Methods: ORAL Shift (NCT02831855) was a global Phase 3b/4 study in pts aged ≥ 18 years with moderate to severe RA and an inadequate response to MTX. Pts received OL tofacitinib MR 11 mg QD + MTX (tofacitinib + MTX) for 24 weeks; those achieving low disease activity (LDA; Clinical Disease Activity Index [CDAI] ≤ 10) at Week (W)24 entered the 24-week double-blind (DB) MTX withdrawal phase, where the primary endpoint was assessed (data reported elsewhere).1 Outcomes from the OL phase, reported descriptively here, include: mean change from baseline (BL) to W12 and W24 in disease activity measures, and PROs; rates of ACR and HAQ-Disability Index (DI) response, and LDA and remission, at W12 and W24 (see Table 1); and safety (see Table 2).

Results: In the OL phase, 694 pts received tofacitinib + MTX. Most pts were female (76.7%), white (85.6%), with a mean age of 56.8 years and mean RA duration of 8.8 years. At W24 (end of the OL phase), 526 (75.8%) pts achieved CDAI-defined LDA (Table 1). In the OL phase, Disease Activity Score in 28 joints, ESR (DAS28-4[ESR]) improved with mean (standard deviation) changes from BL of ‑1.96 (1.19) and -2.67 (1.25) at W12 and W24, respectively (Table 1). Mean changes from BL at W12 and W24 showed improvements in all other efficacy outcomes and PROs (Table 1). ACR20/50/70 and HAQ-DI response rates, and LDA and remission rates, improved from W12 to W24 (Table 1). Adverse events (AEs), serious AEs, and discontinuations due to AEs were reported by 52.2%, 2.9%, and 5.9% of pts, respectively; no deaths were reported (Table 2). The most common AEs were nasopharyngitis and upper respiratory tract infections. AEs of special interest each occurred in ≤ 1% of pts (Table 2).

Conclusion: Tofacitinib MR 11 mg QD + MTX improved disease activity and PROs in pts with moderate to severe RA and an inadequate response to MTX. No new safety risks were observed. Efficacy and safety in this OL phase appeared consistent with that of tofacitinib immediate-release 5 mg twice daily2 and with the DB phase of ORAL Shift.1

  1. Cohen SB et al. Ann Rheum Dis 2019; 78: A260.
  2. Bird P et al. J Clin Rheumatol 2019; 25: 115-126.
  3. Felson DT et al. Arthritis Rheum 2011; 63: 573-586.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by Jennifer Arnold of CMC Connect and funded by Pfizer Inc.


Disclosure: S. Cohen, AbbVie, 2, 5, Eli Lilly, 2, 5, Genentech, 2, 5, Gilead, 2, 5, Pfizer Inc, 2, 5; J. Pope, AbbVie, 5, Abbvie, 5, Actelion, 5, Actellion, 5, Amgen, 2, 5, AstraZeneca, 2, Astra-Zeneca, 2, Bayer, 2, 5, BMS, 2, 5, Eicos Sciences, 5, Eli Lilly & Company, 5, Eli Lilly and Company, 5, EMERALD, 5, Emerald, 5, Genzyme, 5, Janssen, 5, Lilly, 5, Merck, 2, 5, Novartis, 5, Pfizer, 2, 5, Roche, 2, 5, Sandoz, 5, Sanofi, 5, Seattle Genetics, 2, UCB, 2, 5, 8; B. Haraoui, AbbVie, 2, 5, 8, Pfizer Inc, 2, 5, 8, Amgen, 2, 5, 8, Eli Lilly, 2, 5, 8, Merck, 2, 5, 8, UCB, 2, 5, 8, Celgene, 2, 5, 8, Sandoz, 2, 5, 8; E. Mysler, AbbVie, 2, 8, Bristol-Myers Squibb, 8, Eli Lilly, 2, 8, Novartis, 2, Pfizer Inc, 2, 8, Roche, 2, 8, Sanofi, 8; A. Diehl, Pfizer Inc, 1, 3; T. Lukic, Pfizer Inc, 1, 3; S. Liu, Pfizer Inc, 1, 3; L. Stockert, Pfizer Inc, 1, 3; S. Menon, Pfizer Inc, 1, 3; E. Keystone, Abbvie, 2, 5, 8, Amgen, 2, 5, 8, AstraZeneca, 5, Astra-Zeneca, 5, Biotest, 5, BMS, 2, 5, 8, Celltrion, 5, Crescendo, 5, Crescendo Bioscience, 5, F. Hoffmann-La Roche Inc, 2, 5, 8, Genentech, 5, Genentech Inc., 5, Genzyme, 5, Gilead, 2, 5, Gilead Sciences, Inc., 5, Janssen, 2, 5, 8, Lilly, 2, 5, 8, Merck, 5, 8, Pfizer, 2, 5, 8, Pfizer Pharmaceuticals, 2, 5, 8, Roche, 2, 5, 8, Sandoz, 5, Sanofi, 2, 5, 8, Sanofi-Aventis, 2, 8, UCB, 5, 8.

To cite this abstract in AMA style:

Cohen S, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, Liu S, Stockert L, Menon S, Keystone E. Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-tofacitinib-modified-release-11-mg-once-daily-mtx-in-ra-patients-with-an-inadequate-response-to-mtx-open-label-phase-results-from-a-global-phase-3b-4-mtx-withdrawal-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-tofacitinib-modified-release-11-mg-once-daily-mtx-in-ra-patients-with-an-inadequate-response-to-mtx-open-label-phase-results-from-a-global-phase-3b-4-mtx-withdrawal-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology